[HTML][HTML] Contribution of pulmonary function tests (PFTs) to the diagnosis and follow up of connective tissue diseases

N Ciancio, M Pavone, SE Torrisi, A Vancheri… - Multidisciplinary …, 2019 - Springer
Abstract Introduction Connective Tissue Diseases (CTDs) are systemic autoimmune
conditions characterized by frequent lung involvement. This usually takes the form of …

[HTML][HTML] Patients with interstitial lung disease secondary to autoimmune diseases: how to recognize them?

D Sambataro, G Sambataro, F Pignataro… - Diagnostics, 2020 - mdpi.com
The diagnostic assessment of patients with Interstitial Lung Disease (ILD) can be
challenging due to the large number of possible causes. Moreover, the diagnostic approach …

The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study

SE Torrisi, B Ley, M Kreuter… - European …, 2019 - Eur Respiratory Soc
Background The gender–age–physiology (GAP) model was developed to predict the risk of
death. Comorbidities are common in idiopathic pulmonary fibrosis (IPF) and may impact on …

[HTML][HTML] Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study

DM Jovanovic, M Šterclová, N Mogulkoc… - Respiratory …, 2022 - Springer
Background Patients with idiopathic pulmonary fibrosis (IPF) frequently have multiple
comorbidities, which may influence survival but go under-recognised in clinical practice. We …

Guidelines of the Polish Respiratory Society for diagnosis and treatment of idiopathic pulmonary fibrosis

WJ Piotrowski, I Bestry, AJ Białas, PW Boros… - … in Respiratory Medicine, 2020 - mdpi.com
Guidelines of the Polish Respiratory Society for diagnosis and treatment of idiopathic pulmonary
fibrosis Page 1 PRACA ORYGINALNA 42 GUIDELINES AND RECOMMENDATIONS …

Evolution and treatment of idiopathic pulmonary fibrosis

SE Torrisi, N Kahn, C Vancheri, M Kreuter - La Presse Médicale, 2020 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is a chronic and devastating disease of unknown
etiology, characterized by irreversible morphological changes, ultimately leading to lung …

Comorbidity in idiopathic pulmonary fibrosis-what can biomarkers tell us?

TM Alfaro, C Robalo Cordeiro - Therapeutic Advances in …, 2020 - journals.sagepub.com
Idiopathic pulmonary fibrosis (IPF) is characterized by progressive parenchymal scarring,
leading to dyspnoea, respiratory failure and premature death. Although IPF is confined to the …

[HTML][HTML] Delineating excess comorbidities in idiopathic pulmonary fibrosis: an observational study

B Ozaltin, R Chapman, MQU Arfeen, N Fitzpatick… - Respiratory …, 2024 - Springer
Background Our study examined whether prevalent and incident comorbidities are
increased in idiopathic pulmonary fibrosis (IPF) patients when compared to matched chronic …

[HTML][HTML] The prevalence of pulmonary hypertension assessed using the pulmonary vein‐to‐right pulmonary artery ratio and its association with survival in West …

E Roels, A Fastrès, AC Merveille, G Bolen… - BMC Veterinary …, 2021 - Springer
Background Pulmonary hypertension (PH) is a known co-morbidity in West Highland white
terriers (WHWTs) affected with canine idiopathic pulmonary fibrosis (CIPF). The pulmonary …

[HTML][HTML] Pharmacological treatment in Idiopathic Pulmonary Fibrosis: current issues and future perspectives

E Sciacca, G Muscato, L Spicuzza… - Multidisciplinary …, 2024 - ncbi.nlm.nih.gov
Idiopathic pulmonary fibrosis (IPF) represents a fibrotic interstitial lung disease characterized
by uncertain etiology and poor prognosis. Over the years, the path to effective treatments …